Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Operating Expenses history runs 14 years deep, the most recent figure standing at $116.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 23.82% year-over-year to $116.3 million in Q1 2026; TTM through Mar 2026 was $456.6 million, a 35.37% increase from a year earlier, with the FY2025 full-year figure at $434.2 million, up 45.07% from the prior year.
• Operating Expenses fell to $116.3 million in Q1 2026 per VRDN's latest filing, from $122.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $122.9 million in Q4 2025 and bottomed at $26.1 million in Q1 2022.
• The 5-year median for Operating Expenses is $72.3 million (2024), against an average of $73.0 million.
• Across the five-year window, Operating Expenses surged 178.0% in 2023 and declined 22.88% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $49.2 million in 2022, then jumped by 45.51% to $71.6 million in 2023, then climbed by 22.35% to $87.5 million in 2024, then jumped by 40.36% to $122.9 million in 2025, then declined by 5.35% to $116.3 million in 2026.
• Per Business Quant, the three latest VRDN Operating Expenses figures stand at $116.3 million (Q1 2026), $122.9 million (Q4 2025), and $110.6 million (Q3 2025).